China Medical University-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2019

  1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 229-240